Latest filing published 09 Jul 2024 for Crinetics Pharmaceuticals, Inc., €274k.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
James Hassard: trading record in brief
James Hassard (senior executive) discloses dealings in 2 companies, chiefly Crinetics Pharmaceuticals, Inc. and Arrowhead Pharmaceuticals, Inc. The record holds 9 filings, for trades running from 7 January 2021 to 5 July 2024.
Every open-market trade on record is a sale: 4 sales worth €2.5M. Besides market trades, the filings include 3 share grants and 2 option exercises. 2024 to date brings no purchases and 2 sales.
Most recently, on 9 July 2024, the filings show an open-market sale worth €612k in Crinetics Pharmaceuticals, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to James Hassard
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 15,000 shares@ US$19.7344.8% of flowCommon StockSEC:0000950170-24-082529:0
- 15,000 shares@ US$19.7345.2% of flowCommon StockSEC:0000950170-24-076871:0
- 1,741 shares@ US$38.1410.0% of flowCommon StockSEC:0001209191-24-005011:0
- 17,000 shares0Common StockSEC:0001209191-24-004612:0
- 14,000 shares0Common StockSEC:0001209191-23-015619:0
- 3,625 shares@ US$89.22100.0% of flowCommon StockSEC:0001209191-21-043137:0
6 of 6 declarations
